Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Nelmastobart in Combination With Docetaxel in Advanced/Metastatic NSCLC
NCT07306624Phase 2Recruiting
- Sponsor
- STCube
- Start
- Jan 2026
- Primary completion
- Aug 2027
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of nelmastobart in non-small cell lung cancer (NSCLC), sponsored by STCube. Primary endpoint: Progression-Free Survival by central reviewer up to 3 years. Started Jan 2026; status: recruiting.
02
Drugs
nelmastobart
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT07306624.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07306624.